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Isoniazid Completion Rates for Latent Tuberculosis Infection among College Students
Managed by a Community Pharmacist
Karl Hess, Pharm.D., Jeff Goad, Pharm.D., MPH, Joanne Wu, MS, Kathleen Johnson,
Pharm.D., MPH, PhD.

Abstract
Objectives: To document nine month and previously recommended six month treatment
completion rates for latent tuberculosis infection (LTBI) in a pharmacist-managed LTBI clinic
within a community pharmacy on a college campus, and to describe patient characteristics of
those enrolled. Participants: University students diagnosed with LTBI. Methods: The authors
conducted a retrospective review of existing pharmacy records from 2000 to 2006. Main
outcome measures included six and nine month LTBI treatment completion rates, total isoniazid
(INH) tablets taken, characteristics of completers versus non-completers, average time to
treatment completion, and reported adverse drug events. Results: The overall nine month
completion rate was 59% and the six month completion rate was 67%. Among those not
completing treatment, 15.2% experienced fatigue and 2.2% experienced a rash (p=0.04 and
p=0.03). Conclusion: LTBI clinics are a unique niche for community pharmacies and can
provide individualized patient care to ensure LTBI treatment adherence, monitoring for disease
progression, and safety of INH.

Globally, tuberculosis remains a significant cause of morbidity and mortality. It is
estimated that one-third of the world’s population is infected with tuberculosis while nine million
new cases of disease were reported in 2004.1, 2 In 2005, 14,097 cases of tuberculosis were
reported in the United States. Of these cases, 55% occurred amongst foreign-born individuals,
which represents a dominant factor in sustained rates of active tuberculosis in the United States.35

To reduce the development of active tuberculosis and help eliminate infection worldwide,
individuals with LTBI must be treated appropriately. It is estimated that 9.6 to 14.9 million
people in the United States have been diagnosed with LTBI and thus are at higher risk of
developing active tuberculosis.6-8 Treatment with INH daily for nine months (270 tablets) is the
CDC recommended standard of therapy for LTBI; however, patients may take twelve months to
finish all 270 tablets and still be considered treatment completers. Unfortunately, long term
treatment with INH is problematic since individuals with LTBI generally do not feel
symptomatic and thus may not feel obligated to complete treatment.7 Nine month INH treatment
completion rates are sparsely reported in the literature; however, the CDC’s previously
recommended six month (180 tablets) INH regimen has reported completion rates of between 50
to 60%.7, 9, 10 Discontinuing INH treatment prematurely allows progression to active tuberculosis
and the development of drug-resistance.
At our university, approximately 32,000 students are enrolled annually of which roughly
5,500 are classified as international (non-immigrant visa) students. All incoming international
students are required to have a PPD placed and read in the U.S. within one year prior to their first
semester of enrollment in an attempt to identify and treat those with LTBI. In August 2000 after
an internal quality improvement study revealed that a large proportion of students did not

complete their full course of INH, a pharmacist-managed LTBI clinic was opened in the campus
community pharmacy to help improve patient acceptance of INH and LTBI treatment completion
rates.
Since research that focuses on the community pharmacist’s role and outcomes of care in
the management of LTBI is limited, the objectives of this study were to determine the six and
nine month INH completion rates as well as the characteristics of treatment completers versus
non-completers in our community pharmacy LTBI clinic.
Methods
This study was approved by our institutional review board for human subjects. Patients
included in the analysis were those diagnosed with LTBI by student health clinicians, referred to
the pharmacy LTBI clinic, and able to complete the full nine month INH regimen by December
2005. Successful completion of therapy was defined as taking 270 tablets within a nine to twelve
month period. Six month completion was defined as taking 180 tablets within a six month
period. If patients were given additional tablets to compensate for missed doses, it was recorded
in the clinic’s spreadsheet and the amount of INH dispensed was adjusted accordingly.
The number of tablets taken was assessed by the pharmacist’s count or as self-reported by
the patient if their medication vial was not available at the time of visit. We assumed the number
of tablets taken equaled the number of days between clinic appointments, unless a patient
reported skipping doses and/or the tablet count appeared to have been altered. Data collected also
included age, sex, race/ethnicity, concurrent medications, co-morbidities, self-reported history of
alcohol use, prior INH use, adverse drug events, symptoms of progression to active disease, use
of vitamin B6, physician referral, time to first INH fill, amount of INH taken, and number of
days of treatment. Self-reported history of any alcohol use, concurrent use of other medications,

and co-morbidities were assessed only during the initial visit, unless the patient mentioned any of
these issues during subsequent visits with the pharmacist or if the pharmacist otherwise
determined there was a change. Symptoms of INH-induced hepatotoxicity and other adverse
events were assessed by pharmacist questioning and patient self-report. During each
appointment, patients were counseled on the importance of treating LTBI and were encouraged
to continue taking INH as well as keep all future appointments in the pharmacy’s clinic. All
appointments were scheduled in advance and a reminder was sent by email or phone one week
prior to the visit.
Patients were assumed to be lost to follow-up if they withdrew from the pharmacy clinic
on their own, consistently missed scheduled appointments, or if their physician withdrew them
from the clinic on medical grounds.
Categorical variables were evaluated using the chi-square test and continuous variables
were evaluated using the student’s t-test. Statistical significance was set a priori at 0.05. A
subsequent logistic regression analysis was preformed to identify factors associated with
completion of INH. All data was analyzed using SAS version 9.1 (SAS Institute INC; Cary,
North Carolina).
Results
Three hundred and forty-eight patients with completed data on INH use were available
for analysis. P-values are based on a student’s t-test for continuous variables and chi-square test
for categorical variables. The majority of patients who enrolled in the clinic were male (56.3%),
had a mean age of 24.2 ± 4.8 years, and most were of Asian ethnicity (63.5%). Patients were
generally healthy as few co-morbidities (9.2%) and use of concurrent medications (8.9%) were
reported. The average time from the initial screening, diagnosis, and referral at the student health

center to enrollment in the pharmacist-managed LTBI clinic was 4.6 days. Some patients
experienced an adverse drug event (21.6%), but only 7.9% were referred to a student health
physician for further evaluation. Overall, the six month treatment completion rate was 67%, and
the nine month treatment completion rate was 59% for the five years of available data. Since
patients typically started their INH regimen at the beginning of the academic year, we analyzed
yearly completion rates from August to July of each year. Six month completion rates ranged
from 55 to 74% and nine month completion rates ranged from 50 to 63% depending upon the
year of study. Of those patients that completed 6 months of treatment, 88% progressed to
complete the full nine month course of therapy in the allotted time.
Overall, 41% of patients withdrew from the clinic. Of these patients, 52.5% withdrew on
their own, citing a lack of perceived treatment benefit and 41.2% were discharged back to their
primary care provider for non-compliance with their scheduled follow up appointments. Only
6.3% of patients had their treatment discontinued by their physician. Over a third (36%)
discontinued therapy after the first three months. Those not completing treatment were more
likely than those that did complete treatment to have developed a rash (p=0.03) or experienced
fatigue (p=0.04), both possible side effects to INH. In addition, referral to a physician was
observed more often in non-completers (p=0.0002). A subsequent logistic regression analysis
yielded no statistically significant factors associated with treatment completion rates.
Comment
Limited literature suggests pharmacists have a role in the management of tuberculosis.1113

Our 6 month INH completion rate of 67% is consistent with CDC reported rates. At 9 months,

the completion rate dropped to 59%, but with little data on completion rates in the literature, it is
unknown if this is expected. In the few studies available, nine month completion rates have

ranged from 65 to 100%; however, their location and population differ significantly from our
own.14-16 Additionally, research on INH completion rates within the community pharmacy or
university setting have not, to our knowledge, been published.
In this study, the average time from a patient’s initial evaluation and diagnosis of LTBI to
enrollment in the LTBI clinic did not differ between those completing and those not completing
treatment (p=0.6), suggesting that patient behavior was similar at baseline. Those patients who
complained of either fatigue or rash as possible side effects to INH treatment after enrollment
were less likely to complete a full course of treatment (p=0.04 and 0.03, respectively). However,
the significance of fatigue causing treatment discontinuation is questionable because we were
unable to determine a baseline level of fatigue prior to the initiation of INH treatment. In
addition, those patients who were later referred to a physician for evaluation of fatigue or the
presence of a rash, were also less likely to complete their INH regimen (p=0.0002).
While 32.8% of patients in our clinic reported alcohol use of any amount at enrollment,
statistically significant differences between those that reported baseline use versus those that did
not in the rates of INH-related adverse drug events such as nausea (p=0.98), vomiting (p=0.98),
or jaundice (p=0.78) were not seen as one might expect with concurrent use. This suggests that
patients adhered to the pharmacists recommendations to avoid heavy alcohol use while enrolled
in the clinic.
Limitations
Tablet counts at pharmacy clinic visit may have been inaccurate as some patients may
have discarded tablets and/or misrepresented the number of tablets taken in order to finish their
treatment within nine months. To lessen this subjective assessment, dispensing records were used
to calculate adherence. Another limitation was that a large percentage of foreign-born

individuals were enrolled in the clinic which may have created the potential for language and
cultural barriers between the pharmacists and patients that were not accounted for, but may have
impacted the outcome of this study.
Since student schedules are typically broken up by a summer break, treatment completion
rates may have been affected as a 90-day supply of INH was dispensed during this break with
phone and/or email follow-up. This could explain why those who completed treatment took
longer than the minimum nine months to do so (mean= 10.1 months).
For the purposes of this study, those patients who dropped out, transferred, or graduated
from school were considered lost to follow-up but may have in fact completed treatment
elsewhere. However, this is less likely as most students get their prescriptions filled at the
campus pharmacy.
The ability to generalize our results to a non-university population may be limited due to
the unique characteristics of this population. However, applicability of this study to other
university and college settings is high, particularly since international students comprise a
significant percentage of students today nationwide. This is an important public health issue to
be addressed before international students enter the United States workforce and are potentially
lost to follow up.
Conclusions
With over 450,000 foreign students in U.S. universities in 2005-2006, most coming from
high tuberculosis prevalent countries, rates of LTBI in this population are likely to grow as more
universities implement PPD screening programs.17
At our university, the majority of individuals who were referred to, and enrolled in, our
community pharmacy LTBI clinic were identified as foreign-born. Therefore, since our

university has the largest international student population of any U.S. university, this model of
LTBI pharmacy-based clinic care could be implemented at other institutions with smaller
international populations.17
Community pharmacy-based LTBI clinics represent a unique niche for pharmacy and can
serve an important public health function by providing individuals and communities another
option in which to receive comprehensive management, counseling, and support to help
encourage LTBI treatment adherence and completion rates.

References:
1. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Global burden of tuberculosis:
estimated incidence, prevalence, and mortality by country. JAMA. 1999;282:677-686.
2. WHO. Global tuberculosis control: surveillance, planning, financing. Available at
http://www.who.int/tb/publications/global_report/en. Accessed June 19, 2006.
3. CDC. Reported Tuberculosis in the United States, 2005. Available at:
http://www.cdc.gov/tb/surv/surv2005/default.htm. Accessed June 19, 2006.
4. McKenna MT, McCray E, Onorato I. The epidemiology of tuberculosis among foreign-born
persons in the United States, 1986 to 1993. N Eng J of Med. 1995;332:1071-1076.
5. Talbot EA, Moore M, McCray E, Binkin NJ. Tuberculosis among foreign-born persons in the
United States, 1993-1998. JAMA. 2000;284:2894-2900.
6. CDC. Controlling tuberculosis in the United States. MMWR Morb Mortal Wkly Rep.
2005;54(RR-12):1-69.
7. CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Morb
Mortal Wkly Rep. 2000;49(RR-6):1-43.
8. Dooley KE, Sterling TR. Treatment of latent tuberculosis infection: challenges and prospects.
Clin Chest Med. 2005;26:313-326.
9. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive
therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999;281:1014-1018.
10. LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health
clinic. Am J Respir Crit Care Med. 2003;168:443-447.
11. Coleman LT, Adams WC, Gong WC. Pharmacist as a primary-care provider in a tuberculosis
clinic. Am J Health Syst Pharm. 1983;40:278-281.
12. Dayton CS. Pharmacist involvement in a tuberculosis outpatient clinic. Am J Health Syst
Pharm. 1978;35:708-710.
13. Sterling TR, Bethel J, Goldberg SV, Weinfurter P, Yun L, Horsburgh CR. The scope and
impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir
Crit Care Med. 2006;173:927-931.

14. Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment
completion and costs of a randomized trial of rifampin for four months versus isoniazid for nine
months. Am J Respir Crit Care Med. 2004;170:445-449.
15. Cook PP, Maldonado RA, Yarnell CT, Holbert D. Safety and completion rate of short-course
therapy for treatment of latent tuberculosis infection. Clin Infect Dis. 2006;43:271-275
16. Tavitian SM, Spalek VH, Bailey RP. A pharmacist-managed clinic for treatment of latent
tuberculosis infection in health care workers. Am J Health Syst Pharm. 2003;60:1856-1861.
17. Bollag B. Enrollment of foreign students holds steady. Chronicle of Higher Education.
2006;53(13):A44-46.

